Quinishal

Quinishal
Quinishal is indicated mainly in the uncomplicated strains of P. falciparum malaria. Consideration must be given to the WHO guidelines and to local health authorities
Product | Molecule |
---|---|
Quinishal Suspension |
Quinine |
Quinishal Injectables |
Quinishal |
Molecule: Quinine
Formulation: Quinine Sulphate Suspension 100 mg/5 ml
Packaging Unit: 60ml Suspension
Dosage: For the treatment of P. falciparum Malaria a course usually lasts 7 days.
Molecule: Quinishal
Formulation: Quinishal 250mg/2ml, 500mg/2ml, 600mg/2ml Injection
Packaging Unit: 100 Ampoules
Dosage: For the treatment of P. falciparum Malaria a course usually lasts 7 days.
Indications
Quinishal is indicated mainly in the uncomplicated strains of P. falciparum malaria. Consideration must be given to the WHO guidelines and to local health authorities recommendations based on the prevalence of resistance to antimalarial agents.
Pharmacological Class
Pharmacological Properties
Mechanism Of Action
Quinine is a rapidly acting blood schizontocide. It inhibits protein synthesis by preventing strand separation and therefore DNA replication and transcription to RNA.
Side Effects
Contraindications
Quinine and its salts are contra-indicated in patients with a history of hypersensitivity to quinine and in patients with tinnitus or optic neuritis and especially when this takes the form of cutaneous, angioedematous, visual, or auditory symptoms. Quinine should be discontinued immediately if evidence of haemolysis appears. As quinine has been implicated in precipitating blackwater fever, it is generally contraindicated in patients who have already suffered an attack. Quinine should be avoided in patients with myasthenia gravis, as it may aggravate their condition.
Observations
Recent Posts